John L. Villano, Md, Phd

This study tested whether a combination of two immunotherapy drugs (durvalumab and tremelimumab) could slow the growth of recurrent solid tumors that have a high number of genetic mutations. It involved 14 adult patients whose cancer had returned or stopped responding to prior tr…

This study tested if a short, targeted dose of radiation given right before starting standard immunotherapy could improve results for people with advanced lung or head/neck cancer. The idea was that radiation might release cancer markers to help the immune drugs work better. Rese…